Wednesday, October 18, 2017
Eagle Pharmaceuticals, Inc. announced that the Company has been issued a new patent related to its RYANODEX® formulation (dantrolene sodium) by the United States Patent and Trademark Office (USPTO). Patent number 9,789,090 will expire in June 2022. The USPTO has now issued seven patents in the RYANODEX family of patents expiring from 2022 to 2025. The ‘090 patent is directed to a method of treating non-normothermia associated with recreational drug use utilizing Eagle’s RYANODEX formulation.
“We see significant value in RYANODEX and will continue to advance our work with multiple indications for which we believe the product could save lives. This additional patent strengthens our patent estate surrounding RYANODEX so that we may protect the value of our dantrolene sodium portfolio for many years to come,” stated Scott Tarriff, Chief Executive Officer of Eagle Pharmaceuticals.
RYANODEX is approved and marketed for the treatment of malignant hyperthermia. Eagle is currently exploring the use of RYANODEX for the treatment of multiple additional indications.
